Literature DB >> 8317400

Epidemiology of hepatitis C among veterans with alcoholic liver disease. The VA Cooperative Study Group 275.

C L Mendenhall1, T Moritz, S Rouster, G Roselle, A Polito, S Quan, R K DiNelle.   

Abstract

Of 288 patients with alcoholism and various stages of alcoholic hepatitis, 18.4% (53 of 288) reacted serologically for hepatitis C (HCV). An evaluation of the risk factors associated with HCV indicated that parenteral drug use, even in the distant past, increased the risk for infection 10.1-fold (p = 0.0001). Ethnicity was also a significant, independent risk factor. Minorities (i.e., African-Americans or Hispanic-Americans) had a 2.4-fold increase (p = 0.038). Prior blood transfusions, even if multiple, showed only a tendency toward increased infections (p = 0.088) in this population. An interaction between age and contact with parenteral drug users was demonstrated such that the risk of HCV infection was increased by contact with drug users. This was further increased with increasing age (p = 0.006). There was no relationship between HCV reactivity and the severity of the liver disease; however, the liver injury appeared to be accelerated since it occurred at a younger age (p = 0.0001) and was associated with more frequent hospitalizations (p = 0.0005).

Entities:  

Mesh:

Year:  1993        PMID: 8317400

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  10 in total

1.  Assessment of liver histology in chronic alcoholics with and without hepatitis C virus infection.

Authors:  S Anderson; C L Nevins; L K Green; H El-Zimaity; B S Anand
Journal:  Dig Dis Sci       Date:  2001-07       Impact factor: 3.199

2.  How are abnormal results for liver function tests dealt with in primary care? Audit of yield and impact.

Authors:  P Sherwood; I Lyburn; S Brown; S Ryder
Journal:  BMJ       Date:  2001-02-03

3.  Interaction of alcohol and hepatitis C virus infection on severity of liver disease.

Authors:  C L Nevins; H Malaty; M E Velez; B S Anand
Journal:  Dig Dis Sci       Date:  1999-06       Impact factor: 3.199

4.  Higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males.

Authors:  Donna L White; Shariar Tavakoli-Tabasi; Jill Kuzniarek; Rhia Pascua; David J Ramsey; Hashem B El-Serag
Journal:  Hepatology       Date:  2011-12-14       Impact factor: 17.425

Review 5.  Psychiatric and substance use disorders in individuals with hepatitis C: epidemiology and management.

Authors:  Jennifer M Loftis; Annette M Matthews; Peter Hauser
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 6.  Current concepts and controversies in the treatment of alcoholic hepatitis.

Authors:  Catherine Rongey; Neil Kaplowitz
Journal:  World J Gastroenterol       Date:  2006-11-21       Impact factor: 5.742

7.  Combined effects of alcohol and hepatitis C: a secondary analysis of alcohol use biomarkers and high-risk behaviors from two medication trials for alcohol dependence.

Authors:  Jennifer G Plebani; Carlos F Tirado; Helen M Pettinati; Kyle M Kampman; Joseph R Volpicelli; David W Oslin
Journal:  Addict Behav       Date:  2009-09-10       Impact factor: 3.913

8.  Management practices of hepatitis C virus infected alcoholic hepatitis patients: A survey of physicians.

Authors:  Ashwani K Singal; Habeeb Salameh; Anjna Singal; Sarat C Jampana; Daniel H Freeman; Karl E Anderson; Don Brunder
Journal:  World J Gastrointest Pharmacol Ther       Date:  2013-05-06

9.  Positive CAGE screen correlates with cirrhosis in veterans with chronic hepatitis C.

Authors:  Ahmad Kamal; Ramsey Cheung
Journal:  Dig Dis Sci       Date:  2007-04-06       Impact factor: 3.199

10.  Racial differences in the association between adiposity measures and the risk of hepatitis C-related liver disease.

Authors:  Donna L White; Shahriar Tavakoli-Tabasi; Jill Kuzniarek; David J Ramsey; Hashem B El-Serag
Journal:  J Clin Gastroenterol       Date:  2012-10       Impact factor: 3.062

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.